Adaptimmune Therapeutics Faces Listing Rule Notice
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-rule, compliance
TL;DR
Adaptimmune got a notice about failing a listing rule - could be trouble.
AI Summary
Adaptimmune Therapeutics PLC announced on September 22, 2025, that it received a notice regarding its failure to meet a continued listing rule or standard for its securities. The company is currently evaluating the notice and will provide further updates as necessary.
Why It Matters
This notice could impact the trading and liquidity of Adaptimmune's securities, potentially affecting investor confidence and the company's ability to raise capital.
Risk Assessment
Risk Level: medium — Failure to meet listing standards can lead to delisting, which significantly impacts a company's stock value and accessibility.
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Registrant
- September 22, 2025 (date) — Date of earliest event reported
FAQ
What specific listing rule did Adaptimmune Therapeutics PLC fail to meet?
The filing does not specify the exact listing rule that Adaptimmune Therapeutics PLC failed to meet, only that a notice was received regarding failure to satisfy a continued listing rule or standard.
What is the date of the notice regarding the listing rule?
The earliest event reported, which includes the notice, is dated September 22, 2025.
What actions is Adaptimmune Therapeutics PLC taking in response to the notice?
Adaptimmune Therapeutics PLC is currently evaluating the notice and will provide further updates as necessary.
What is the potential consequence of failing to meet listing standards?
Failure to meet continued listing standards can lead to the transfer of a company's listing or delisting from the exchange.
Where is Adaptimmune Therapeutics PLC incorporated?
Adaptimmune Therapeutics PLC is incorporated in England and Wales.
Filing Stats: 717 words · 3 min read · ~2 pages · Grade level 16 · Accepted 2025-09-26 16:30:18
Key Financial Figures
- $1.00 — , which requires a minimum bid price of $1.00 per share (the "Bid Price Rule"). The
Filing Documents
- adap-20250922x8k.htm (8-K) — 33KB
- 0001104659-25-093882.txt ( ) — 144KB
- adap-20250922.xsd (EX-101.SCH) — 4KB
- adap-20250922_lab.xml (EX-101.LAB) — 16KB
- adap-20250922_pre.xml (EX-101.PRE) — 11KB
- adap-20250922x8k_htm.xml (XML) — 5KB
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 22, 2025, Adaptimmune Therapeutics plc (the "Company") received a written notice from the Nasdaq Hearings Panel (the "Panel") confirming that the Company has been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the "Bid Price Rule"). The Company has until December 1, 2025 to regain compliance with the Bid Price Rule. Failure to regain compliance by December 1, 2025 will result in the delisting of the Company's American Depositary Shares from The Nasdaq Capital Market.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements that are not historical facts and can be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," or the negative of these terms, or other comparable terminology. These statements are based on our current expectations, estimates, and projections about our business and industry, management's beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to the risks described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this current report on Form 8-K speak only as of the date the statements were made and the Company does not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ADAPTIMMUNE THERAPEUTICS PLC Date:September 26, 2025 By: /s/ Margaret Henry Name: Margaret Henry Title: Corporate Secretary